Axial spondyloarthritis: emerging drug targets.
Bilade CherqaouiLuiza M AraujoSimon GlatignyMaxime BrebanPublished in: Expert opinion on therapeutic targets (2021)
Some of the most promising approaches include: (i) modulation of transforming growth factor-β family that could exert a specific role on bone formation; (ii) blockade of granulocyte-macrophage colony-stimulating factor that could reduce type 3 immune responses, and (iii) rebalancing of biased immune response by cytokines such as IL-2 or IL-27 that could favor anti-inflammatory response and sustained drug-free remission. Multiomics tools and artificial intelligence could contribute to identification of optimal targets and help stratify patients for the most appropriate treatment options.
Keyphrases
- immune response
- artificial intelligence
- transforming growth factor
- inflammatory response
- end stage renal disease
- machine learning
- big data
- ejection fraction
- chronic kidney disease
- deep learning
- epithelial mesenchymal transition
- newly diagnosed
- dendritic cells
- toll like receptor
- disease activity
- peritoneal dialysis
- prognostic factors
- adipose tissue
- lps induced
- emergency department
- lipopolysaccharide induced
- patient reported outcomes
- ulcerative colitis
- electronic health record
- recombinant human